Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. RemeGen Co., Ltd.
  6. News
  7. Summary
    9995   CNE1000048G6

REMEGEN CO., LTD.

(9995)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

RemeGen's January-September Loss Widens on Higher Expenses

11/28/2021 | 08:42pm EST


ę MT Newswires 2021
All news about REMEGEN CO., LTD.
01/12Hong Kong Stocks Jump to Seven-Week High; RemeGen Climbs 9% on Shanghai IPO Approval
MT
01/12Chinese Regulator Approves RemeGen's Shanghai IPO Application; Shares Jump 9%
MT
01/05Chinese Regulators Grant Conditional Marketing Approval to Remegen's Urothelial Carcino..
MT
01/05RemeGen Co., Ltd. Announces National Medical Products Administration Grants Conditional..
CI
2021RemeGen's Trustee Acquires Shares Under Share Award, Trust Scheme
MT
2021RemeGen Buying Filtration Devices From Contract Development Firm
MT
2021Chinese Regulators Accept RemeGen's Application for Clinical Trial of Combination Drugs..
MT
2021China Includes Two RemeGen Drugs to New National Reimbursement List
MT
2021RemeGen Shareholders to Vote Dec. 20 on Employee Incentive Tied to Shanghai IPO
MT
2021RemeGen's Telitacicept and Disitamab Vedotin Enter China's National Reimbursement Drug ..
CI
More news
Financials
Sales 2021 1 198 M 189 M 189 M
Net income 2021 20,1 M 3,17 M 3,17 M
Net cash 2021 2 697 M 425 M 425 M
P/E ratio 2021 -334x
Yield 2021 -
Capitalization 27 820 M 4 379 M 4 384 M
EV / Sales 2021 21,0x
EV / Sales 2022 17,9x
Nbr of Employees 1 735
Free-Float -
Chart REMEGEN CO., LTD.
Duration : Period :
RemeGen Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REMEGEN CO., LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Last Close Price 56,79 CNY
Average target price 112,83 CNY
Spread / Average Target 98,7%
EPS Revisions
Managers and Directors
Jian Min Fang CEO, Executive Director & Chief Scientific Officer
Dao Tian Fu President
Jia Li Chief Financial Officer & Joint Secretary
Weidong Wang Chairman
Ruyi He Executive Director & Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
REMEGEN CO., LTD.-10.65%4 379
GILEAD SCIENCES, INC.-1.16%90 027
REGENERON PHARMACEUTICALS-2.58%64 327
VERTEX PHARMACEUTICALS6.58%59 510
WUXI APPTEC CO., LTD.-3.88%52 722
BIONTECH SE-23.97%47 338